Skip to content
Doug Maready, MD
Newsletter ·

← All issues

Newsletter · Issue of March 12, 2026

Have You Heard of The New GLP-1 Changes?

What's new in obesity treatment — a new Wegovy pill, the Zepbound KwikPen, the pipeline ahead, and what I'm seeing in clinic.

By Doug Maready, MD 6 min read Published March 12, 2026
A hand pinches a small white oral GLP-1 tablet between thumb and forefinger against a soft gray background.

A new GLP-1 pill, another one coming soon, and the new Zepbound KwikPen device are just a few of the changes in the world of GLP-1 medications over the past few months. These changes are reshaping the tools that doctors and patients have available for treatment.

Obesity is a chronic, treatable disease.

We've also seen more scientific evidence reinforcing what the data has been saying for years — and it keeps getting stronger. These medications are the most important medical breakthroughs I've witnessed in my career.

If you'd like a deeper explanation of how GLP-1 medications work, watch my earlier podcast discussion with expert pharmacist Casey.


The New Wegovy Pill Has Launched

The Wegovy (semaglutide) pill was released 1/5/2026. This is a huge milestone — it's the first oral GLP-1 approved for obesity treatment and has the same efficacy as the injectable version.

Is It Covered by Your Insurance?

Check the Wegovy website for Cost and Coverage information. They have a tool that can check your insurance for coverage, get the savings card, or give details about the cash pay options.

A hand holds a Wegovy (semaglutide) oral tablet package — 1.5 mg, 30 tablets — in front of a dark background.

Wegovy Cash Pricing (No Insurance Coverage)

Cash pricing continues to evolve as manufacturers attempt to improve access, and these numbers will keep changing. As of now, here are the prices:

Side-by-Side: Wegovy Pill vs. Injection

Feature Pill Injection
DosingDailyWeekly
Starting Price$149 / month$199 / month (first 2 months)
Higher Dose Pricing$299 / month$399 / month
Insurance EligibleYesYes

Where to Obtain (Cash Pay)

NovoCare Pharmacy (manufacturer direct) can ship the medication directly to you or send it to a local pharmacy for pickup.


The New Zepbound KwikPen

A capped Zepbound KwikPen 2.5 mg — a multi-dose tirzepatide injection pen.

Lilly just released the Zepbound KwikPen, which contains a full month of medication in one device. It's easier to use than the vials and reduces device waste compared to the single-dose pens. It's not covered by insurance yet, but should be soon.

Details are available on the LillyDirect website, including device comparisons and administration instructions.

Insurance Coverage

Check cost and coverage on the Zepbound website and sign up for the savings offered for commercial insurance patients.

Zepbound Cash Pricing (via LillyDirect)

Cash-pay prescriptions can be sent by your doctor to LillyDirect, Lilly's direct pharmacy. The vial and KwikPen are available here, but you can also get the single-dose pens here if covered by insurance. Medication can be shipped to your home or picked up at Walmart Pharmacy. You can also use the Zepbound KwikPen Self-Pay Savings Card at any participating pharmacy to get the same price.

Hands hold a capped Zepbound KwikPen demo pen, showing the label and dose dial.
Hands hold an uncapped Zepbound KwikPen demo pen, showing the needle end of the device.

Zepbound Dose and Pricing — Vials or KwikPen

DoseMonthly Cost
2.5 mg$299
5 mg$399
Higher doses$449

Prices may continue to change as the landscape evolves.


New Medications Coming

The upcoming medications are very exciting.

Orforglipron (oral GLP-1) has been submitted to the FDA for approval and a decision is expected in the coming months.

Retatrutide (Triple Agonist — Weekly Injection) is in late-phase (Phase 3) trials. Study results (TRIUMPH Study) showed an amazing 24–29% mean weight loss at 48 weeks, depending on dose. This is better than all the other medications, and it's expected to come out in 2027.

CagriSema (Cagrilintide + Semaglutide combination) is a combination amylin analog + GLP-1 medication. It's been submitted to the FDA for approval and a decision is expected in late 2026.

These new medications are a huge step forward and will help so many more patients.


What I'm Seeing

My patients are experiencing:

  • Improved metabolic health
  • Sustainable behavior change
  • Increased ability to follow nutrition and exercise plans
  • Better quality of life

We also see side effects, but help our patients work through them. Working with an experienced clinician is essential — with proper guidance, most patients can successfully navigate dose adjustments and tolerability issues.

These medications are tools — not replacements for nutrition, movement, sleep, and behavioral support — but they make those foundational habits more achievable.

The Bottom Line
Obesity is a chronic disease and it is treatable. We now have tools that meaningfully improve health outcomes. If you're considering treatment, speak with a clinician experienced in obesity medicine — and if you're a clinician, stay tuned for the latest updates in obesity medicine.

Get the next one in your inbox.

Weekly notes on obesity medicine, treatment updates, and clinical perspectives from Doug Maready, MD.

We’ll only email you the newsletter and occasional related updates. Unsubscribe anytime.